What Is My Pharmacy Business Worth in 2026?
Most independent pharmacy businesses sell for 2.0x to 4.0x SDE or 3.60x to 4.75x EBITDA in 2026, with specialty and compounding pharmacies commanding 5.0x to 7.0x EBITDA and scaled multi-location platforms reaching 9.0x or higher. The active buyer pool includes CVS Health picking up prescription files from closed independents, Kroger and Albertsons absorbing regional pharmacies, and private equity platforms like Sycamore Partners (which took Walgreens private in 2025), Ardian, CapVest, and Frazier Healthcare Partners hunting specialty and LTC assets.
At a Glance
- Typical Multiple: 2.0x–4.0x SDE / 3.60x–4.75x EBITDA
- Active Buyers: CVS, Kroger, Albertsons + PE-backed specialty platforms
- Typical Timeline: 6–12 Months
- Revenue Sweet Spot: $2M–$8M Retail / $5M–$25M Specialty
Who this is for: Independent retail pharmacy owners, specialty and compounding pharmacy operators, long-term care pharmacy principals, and regional chain owners trying to understand what their business is actually worth before they talk to a buyer.
How a Pharmacy Business Is Valued
A pharmacy sale is priced off of earnings — not revenue. For independents under $3M in sales, that earnings number is SDE (seller's discretionary earnings): net income plus owner compensation, perks, and one-time costs. Above roughly $3M in revenue, buyers shift to EBITDA because they expect a professional pharmacist-in-charge to stay post-close. The script file, inventory, DEA license standing, and non-compete exit terms all attach to the deal but earnings anchor the price.
The SDE multiple for a typical independent retail pharmacy transacts in a 2.45x to 3.38x band. Higher-volume stores — think $4M+ in sales with strong front-end margin and diversified payer mix — push toward 4.0x SDE. Specialty pharmacies move into EBITDA territory fast because buyers underwrite drug-mix durability and payer contracts, and those businesses clear 5.0x to 7.0x EBITDA regularly. I've seen platform specialty assets trade north of 9.0x when the drug mix is diversified and payer relationships are stable.
Current Multiples for Pharmacy Businesses
In 2026, here's where the market is clearing. Independent retail at $1M–$3M SDE: 2.0x–3.5x. Higher-volume retail independents with growth: 3.5x–4.0x SDE. Compounding pharmacies (503A or 503B): 4.5x–6.0x EBITDA. Specialty pharmacy independents: 5.0x–7.0x EBITDA. Scaled specialty platforms with diversified payer contracts: 9.0x–12.0x EBITDA. Long-term care pharmacies with institutional contracts: 5.0x–8.0x EBITDA depending on contract length and renewal history.
The spread inside each band comes down to payer mix, DIR fees exposure, gross margin trend, and whether the PIC (pharmacist-in-charge) is the owner or a transferable employee. I've seen two pharmacies with identical $600K SDE sell six months apart — one at 2.3x, one at 3.7x — because one had 68% of scripts through PBMs and the other had balanced cash-pay compounding plus a small LTC contract book.
Who's Buying Pharmacies in 2026
With Rite Aid's estate fully wound down and Walgreens now in private hands under Sycamore Partners, the buyer landscape has tightened at the top but broadened in the middle. CVS Health is still the most active strategic — typically buying prescription files rather than locations. Kroger, Albertsons, and Giant Eagle have been active acquirers of regional pharmacy assets, especially those attached to supermarket footprints.
On the PE side, Ardian, CapVest, Frazier Healthcare Partners, and Nautics are actively pursuing specialty pharmacy and pharmaceutical service platforms. Independent Pharmacy Cooperative and Pace Alliance recently combined their buying group footprints, creating consolidation pressure at the buying-group level that's also producing M&A as smaller groups get rolled up.
For the typical independent retail seller, the most likely buyer is either a regional independent operator expanding footprint, a local pharmacist stepping into ownership, or a supermarket chain doing a file buy. Specialty and LTC sellers have a meaningfully deeper PE bench. Find more industry-specific buyer commentary on my pharmacy business valuation hub.
What Makes a Pharmacy Worth More
The levers that move a multiple up: script count stability (12-month trailing scripts flat or growing, not declining), gross margin above the independent average of 22%, payer mix that isn't over-concentrated on one PBM, a non-owner PIC willing to sign a retention agreement, clean DEA and Board of Pharmacy history, diversified revenue (front-end retail, immunizations, MTM, compounding, or adherence packaging), and demonstrated exposure to specialty or high-margin drug categories.
Buyers will add 0.5x to 1.0x on the multiple when they see sustainable growth levers — immunization programs, specialty compounding capability, LTC or hospice contracts, or integration with telehealth platforms. These aren't hypothetical premiums; I've watched them applied in term sheets.
What Hurts Pharmacy Valuations
Five things consistently drag multiples down. Declining script counts — even a 3% annual drop triggers serious discount conversations. DIR fee exposure above industry average. Concentration risk on any one PBM contract over 40%. Any open DEA or Board investigation, even if resolved favorably. Owner-pharmacist dependency where the owner is also the PIC and there is no bench. Reduction of 0.25x to 0.5x on the multiple is typical for unresolved compliance issues, and I've seen deals collapse entirely over undisclosed DEA red flags mid-diligence.
Reimbursement pressure is the macro factor nobody escapes. Buyers in 2026 are modeling 1–3% annual gross margin compression into their returns, so if your gross margin has been flat, they're underwriting future decline. Sellers with expanding margin year-over-year get a disproportionate pricing benefit because they're going against the industry tide.
How Long Does It Take to Sell a Pharmacy Business?
For a typical independent retail pharmacy with clean books and no DEA issues, I run a 6 to 9 month process from engagement to close. Specialty and compounding deals take 9 to 14 months because payer contract diligence is slower and inventory is more complex. Cash-pay compounding operations sometimes close faster than retail because there's no PBM reconciliation headache.
The longest delays I see are always payer transition or DEA license transfer, not the business diligence itself. Buyers will drag their feet when the PIC transition plan is thin. For reference on pacing and process, see the general transaction timelines I lay out across my healthcare practice valuation coverage.
"I closed a $4.8M specialty pharmacy last year where the owner insisted he should get 6.5x EBITDA because that's what he'd read online. The first round of term sheets came in at 4.8x to 5.4x. The reason was simple — 62% of his script volume ran through one specialty PBM contract with 14 months left. We restructured his payer mix over 11 months, brought in two new contracts, and resold at 6.1x. The multiple isn't a number you argue for. It's a number buyers derive from the risks they see in your P&L and your contract stack."
